Follow Us:

FSG Blogs

see all

Global Health Blog RSS

See more posts from the Global Health blog

This blog contains posts from the Global Health impact area at FSG.
Posted by: David Zapol on 11/14/2011

As I prepared to go to the annual tuberculosis (TB) Union meeting in October, friends and colleagues mentioned that they had heard the good news about TB, that incidence is falling. And I would respond that only 0.5% of people who have multi drug resistant TB (MDR-TB) are being treated. I went to Lille, France with my colleagues to roll up our sleeves and do something about this.

Our work over the last six months with Eli Lilly and Company was announced last week: a five-year, $30M commitment to the third phase of the Lilly MDR-TB Partnership, focusing on second line drug supply and access, and health care provider training. With so many problems in MDR-TB, it was not easy to choose a focus. Lilly takes an approach throughout its programs to create long term impact through its activities under the framework of Research, Report and Advocate – you can read more about this work from our client, Tracy Sims in a recent blog post.

Posted by: Rajni Chandrasekhar on 7/12/2011

Recently I was fortunate enough to travel far and wide across China (after an equally exciting trip to Russia) to understand the growing epidemic of multi-drug resistant tuberculosis (MDR-TB). China suffers from the world’s second largest TB epidemic, after India, with approximately 1.4 million new TB patients, and 140,000 TB-related deaths each year.

Posted by: David Zapol on 6/20/2011

Imagine Siberia, swamps, snows and mosquitos, the dark heart of Russian history- prisons and camps and starving farmers. It might be surprising to you that I left Moscow on a midnight flight disheartened about the Russian health system and 24 hours later I am inspired by a Siberian prison doctor.

Follow Us:

Facebook Twitter YouTube LinkedIn RSS